Bendamustine
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2008
- First approval year
- 2008
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Bendamustine
- Molecular weight
- 358.27
- Structure (SMILES)
- Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21
- 1h benzimidazole 2 butanoic acid 5 bis 2 chloroethyl amino 1 methyl
- 1H-BENZIMIDAZOLE-2-BUTANOIC ACID, 5-(BIS(2-CHLOROETHYL)AMINO)-1-METHYL-
- bendamustina
- Bendamustina
- bendamustine
- Bendamustine
- BENDAMUSTINE [HSDB]
- bendamustine [INN]
- BENDAMUSTINE [MI]
- BENDAMUSTINE [VANDF]
- Bendamustine [WHO-DD]
- bendamustine hsdb
- bendamustine inn
- bendamustine mi
- bendamustine vandf
- bendamustine who dd
- ATC classification codes
- L01AA09
Sources for recorded values
- CAS registry numbers
- 16506-27-7
- ChEMBL ID
- CHEMBL487253
- InChIKey
- YTKUWDBFDASYHO-UHFFFAOYSA-N
- PubChem compound IDs
- 65628
- FDA ingredient codes (UNII)
- 9266D9P3PQ
- 134547
- 1114693
- Applicant
- CEPHALON
- Approval date
- 20 Mar 2008
- Application number
- NDA022249
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- bendamustine
- Type
- Synthetic organic
- Drug name stem
- -mustine
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000094
- Subject identifier
- D015456
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000096
- Subject identifier
- D008224
- Condition
- Hodgkin Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Lymphoma, B-Cell, Marginal Zone
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000191
- Subject identifier
- D018442
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Lymphoma, T-Cell, Peripheral
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000211
- Subject identifier
- D016411
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000220
- Subject identifier
- D054198
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Immunoblastic Lymphadenopathy
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000255
- Subject identifier
- D007119
- Condition
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000339
- Subject identifier
- D015464
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Leukemia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Multiple Myeloma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition
- Hematologic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001642
- Subject identifier
- D019337
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001663
- Subject identifier
- D011471
- Condition
- Lymphoma, Non-Hodgkin
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005952
- Subject identifier
- D008228
- Condition
- Leukemia, Plasma Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0006475
- Subject identifier
- D007952
- Condition
- Waldenstrom Macroglobulinemia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0009441
- Subject identifier
- D008258
- Condition
- Lymphoma, B-Cell, Marginal Zone
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000630
- Subject identifier
- D018442
- Condition
- Leukemia, Hairy Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000956
- Subject identifier
- D007943
- Condition
- Lymphoma, Mantle-Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001469
- Subject identifier
- D020522
And 9 more, listed on the interactive page.
- Condition identifier
- EFO_0000095
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000096
- Condition identifier
- EFO_0000183
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000191
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000255
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000403
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000565
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005952
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009441
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000630
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001469
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001938
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001968
- Highest recorded phase
- 2
- Condition identifier
- HP_0000083
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000430
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000432
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000607
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001106
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002083
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002571
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004948
- Highest recorded phase
- 3
And 45 more, listed on the interactive page.
- Event
- anaemia
- Reports
- 249
- Reporting signal score
- 134.772
- Event
- b-cell lymphoma recurrent
- Reports
- 36
- Reporting signal score
- 148.329
- Event
- basal cell carcinoma
- Reports
- 57
- Reporting signal score
- 73.7201
- Event
- chronic lymphocytic leukaemia
- Reports
- 35
- Reporting signal score
- 79.63
- Event
- chronic lymphocytic leukaemia recurrent
- Reports
- 24
- Reporting signal score
- 77.8509
- Event
- covid-19
- Reports
- 94
- Reporting signal score
- 90.1226
- Event
- cytokine release syndrome
- Reports
- 56
- Reporting signal score
- 104.774
- Event
- cytomegalovirus chorioretinitis
- Reports
- 31
- Reporting signal score
- 84.6379
- Event
- cytomegalovirus infection
- Reports
- 123
- Reporting signal score
- 252.239
- Event
- cytomegalovirus infection reactivation
- Reports
- 30
- Reporting signal score
- 76.6057
- Event
- cytopenia
- Reports
- 59
- Reporting signal score
- 106.711
- Event
- diffuse large b-cell lymphoma
- Reports
- 91
- Reporting signal score
- 257.232
- Event
- diffuse large b-cell lymphoma recurrent
- Reports
- 62
- Reporting signal score
- 219.077
- Event
- diffuse large b-cell lymphoma refractory
- Reports
- 21
- Reporting signal score
- 76.8979
- Event
- disease progression
- Reports
- 245
- Reporting signal score
- 293.226
- Event
- febrile neutropenia
- Reports
- 397
- Reporting signal score
- 739.606
- Event
- hypogammaglobulinaemia
- Reports
- 39
- Reporting signal score
- 76.7221
- Event
- infection
- Reports
- 150
- Reporting signal score
- 97.8294
- Event
- infusion related reaction
- Reports
- 109
- Reporting signal score
- 87.8043
- Event
- leukopenia
- Reports
- 118
- Reporting signal score
- 103.978
- Event
- lymphocyte count decreased
- Reports
- 85
- Reporting signal score
- 125.895
- Event
- lymphopenia
- Reports
- 71
- Reporting signal score
- 103.322
- Event
- mantle cell lymphoma
- Reports
- 19
- Reporting signal score
- 59.1493
- Event
- myelodysplastic syndrome
- Reports
- 78
- Reporting signal score
- 143.435
- Event
- neutropenia
- Reports
- 421
- Reporting signal score
- 510.87
And 12 more, listed on the interactive page.
- NCT00076349
- NCT00139841
- NCT00426855
- NCT00547534
- NCT00825149
- NCT00877006
- NCT01059630
- NCT01133158
- NCT01232556
- NCT01294579
- NCT01332968
- NCT01456351
- NCT01458366
- NCT01491841
- NCT01570049
- NCT01594229
- NCT01724021
- NCT01900509
- NCT01929265
- NCT02006485
- NCT02187133
- NCT02626455
- NCT02836639
- NCT02954406
- NCT03311126
And 225 more, listed on the interactive page.
- Dose
- 100 mg/m2 for CLL; 120 mg/m2 for NHL
- Route
- Intravenous
- How often
- On Days 1 and 2 of a 28-day cycle for CLL; on Days 1 and 2 of a 21-day cycle for NHL
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 1
- Polar surface area
- 58.36
- Calculated partition coefficient (ALogP)
- 3.26
- Calculated partition coefficient (XLogP)
- 2.9
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 9
- Heavy atoms
- 23
- Molecular formula
- C16H21Cl2N3O2
- Monoisotopic mass
- 357.1010823
- Natural product
- Yes
- Recorded assays
- 912
- Active assays
- 72
- Confirmatory
- Other
- Screening
- Summary
- Antineoplastic Agents, Alkylating
Related records
Trials (301)
- A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
- A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma
- A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer
- A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
- A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma
- A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia
- A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients
- A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia
- A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma
- A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma
- A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
- A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas
- A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
- A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
- A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
Approved for (2)
- Cancer
- Neoplasm
In development for (33)
- Acute lymphoblastic leukemia Phase 2
- Acute myeloid leukemia Phase 1
- AL amyloidosis Phase 2
- Angioimmunoblastic T-cell lymphoma Phase 3
- B-cell acute lymphoblastic leukemia Phase 1
- B-cell chronic lymphocytic leukemia Phase 3
- B-cell non-Hodgkin lymphoma Phase 1
- Breast cancer Phase 2
- Chronic myeloid leukemia Phase 1
- Classic Hodgkin lymphoma Phase 3
- Cold agglutinin disease Phase 2
- Diffuse large B-cell lymphoma Phase 3
- Follicular lymphoma Phase 3
- Hairy cell leukemia Phase 2
- Hematopoietic and lymphoid system neoplasm Phase 2
- Hodgkins lymphoma Phase 3
- Leukemia Phase 2
- Lymphoid neoplasm Phase 2
- Lymphoma Phase 3
- MALT lymphoma Phase 3